Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10889323 | Journal of Immunological Methods | 2008 | 6 Pages |
Abstract
Neutralizing antibodies (NAbs) can occur in some multiple sclerosis (MS) patients receiving interferon β (IFNβ) therapy. NAbs reduce drug bioavailabity and high NAb titers reduce drug efficacy. We describe the validation of the R. Farrell and G. Giovannoni luciferase reporter gene assay to measure NAbs to INFβ. We assayed 163 sera from IFNβ treated MS patients with an optimized luciferase method and compared the results to those obtained with the reference cytopathic effect (CPE) method using A549 cells and an encephalomyocarditis virus (EMCV). Binding antibodies (BAbs) were measured using a capture ELISA as a screening test for NAbs in the CPE assay. NAb status measured by the luciferase and the ELISA/CPE method did not yield a significant difference. Log10 NAb titers obtained from the luciferase assay and the A549/EMCV CPE methods correlated very well. The inter-assay coefficient of variation for titers was between 17.8-29.3%, and the intra-assay coefficient of variation was between 6.3-15.2%. The luciferase assay is reliable, appropriately sensitive and requires less time than the currently available NAb methods.
Keywords
CPETRURIPAnAbsmyxovirus resistance protein AMxAIFNβEMCVLuciferase reporter gene assayBinding antibodiesNeutralizing antibodiesenzyme linked immunosorbent assaysCytopathic effectinterferoninterferon-betaInterferon betaIFNBABSELISACNScentral nervous systemMultiple sclerosisunitEncephalomyocarditis virus
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Regina Lam, Rachel Farrell, Tariq Aziz, Ebrima Gibbs, Gavin Giovannoni, Sidney Grossberg, Joel Oger,